[1] Flesken-Nikitin A, Hwang CI, Cheng CY, et al. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche [J]. Nature, 2013,495(7440):241-245. [2] Bowen NJ, Walker LD, Matyunina LV, et al. Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells [J]. BMC Medical Genomics, 2009, 71 (2):121-126. [3] Jazedje T, Perin PM, Czeresnia CE, et al. Human fallopian tube:a new source of multipotent adult mesenchymal stem cells discarded in surgical procedures [J]. Journal of Translational Medicine, 2009, 46 (7):801-807. [4] Hosonuma S, Kobayashi Y, Kojo S, et al. Clinical significance of side population in ovarian cancer cells [J]. Human Cell, 2011,24(1):9-12. [5] Chau WK, Ip CK, Mak AS, et al. C-kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of wnt/beta-catenin-atp-binding cassette g2 signaling [J]. Oncogene, 2013,32(22):2767-2781. [6] Cao L, Shao M, Schilder J, et al. Tissue transglutaminase links tgf-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer [J]. Oncogene, 2012,31(20):2521-2534. [7] Bignotti E, Tassi RA, Calza S, et al. Gene expression profile of ovarian serous papillary carcinomas:identification of metastasis-associated genes [J]. American Journal of Obstetrics and Gynecology, 2007,196(3):245 e241-211. [8] Dressman HK, Muramoto GG, Chao NJ, et al. Gene expression signatures that predict radiation exposure in mice and humans [J]. PLoS Medicine, 2007,4(4):e106. [9] Kurrey NK, Jalgaonkar SP, Joglekar AV, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells [J]. Stem cells, 2009,27(9):2059-2068. [10] Medema JP. Cancer stem cells:the challenges ahead [J]. Nature Cell Biology, 2013,15(4):338-344. [11] Abubaker K, Latifi A, Luwor R, et al. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden [J]. Molecular Cancer, 2013,24(12):1601-1609. [12] Steg AD, Bevis KS, Katre AA, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer:clinical cancer research[J].An Official Journal of the American Association for Cancer Research, 2012,18(3):869-881. [13] McAuliffe SM, Morgan SL, Wyant GA, et al. Targeting notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy [J]. Proceedings of the National Academy of Sciences of the United States of America, 2012,109(43):E2939-2948. [14] Cheng W, Liu T, Wan X, et al. Microrna-199a targets cd44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells [J]. The FEBS Journal, 2012,279(11):2047-2059. [15] Nam EJ, Lee M, Yim GW, et al. Microrna profiling of a cd133(+) spheroid-forming subpopulation of the ovcar3 human ovarian cancer cell line [J]. BMC Medical Genomics, 2012, 18(5):601-603. [16] Zhang J, Guo X, Chang DY, et al. Cd133 expression associated with poor prognosis in ovarian cancer:modern pathology : an official journal of the[J].United States and Canadian Academy of Pathology,2012,25(3):456-464. [17] Slomiany MG, Dai L, Tolliver LB, et al. Inhibition of functional hyaluronan-cd44 interactions in cd133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides:clinical cancer research[J].An Official Journal of the American Association for Cancer Research, 2009,15(24):7593-7601. [18] Casagrande F, Cocco E, Bellone S, et al. Eradication of chemotherapy-resistant cd44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin [J]. Cancer, 2011,117(24):5519-5528. [19] Yo YT, Lin YW, Wang YC, et al. Growth inhibition of ovarian tumor-initiating cells by niclosamide [J]. Molecular Cancer Therapeutics, 2012,11(8):1703-1712. [20] Kumar S, Meuter A, Thapa P, et al. Metformin intake is associated with better survival in ovarian cancer: a case-control study [J]. Cancer, 2013,119(3):555-562. [21] Yin G, Alvero AB, Craveiro V, et al. Constitutive proteasomal degradation of twist-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential [J]. Oncogene, 2013,32(1):39-49. [22] Li Y, Zeng H, Xu RH, et al. Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer [J]. Stem Cells, 2009,27(12):3103-3111. [23] Zhang Z, Chen X, Chang X, et al. Vaccination with embryonic stem cells generates effective antitumor immunity against ovarian cancer [J]. International Journal of Molecular Medicine, 2013,31(1):147-153. [24] Dong W, Qiu C, Shen H, et al. Antitumor effect of embryonic stem cells in a non-small cell lung cancer model: Antitumor factors and immune responses [J]. International Journal of Medical Sciences, 2013,10(10):1314-1320. |